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Introduction: Lifelong and expensive immunoglobulin administration is the main therapy for chronic dysimmune polyneu-
ropathies as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN).
Based on recent clinical evidence, this treatment can be administered by intravenous immunoglobulin (IVIg) or subcutaneous
infusions (SCIg) and delivered at home. IVIg, in responsive and stabilized patients, is usually administered in an outpatient
setting with twice a month infusion every 25–35 days (1–2 g/Kg/month). Conversely, SCIg is given at home in most cases
with three to five weekly infusions (1–2 g/Kg/month). This study aims to determine whether SCIg is cost-effective compared
with IVIg from a regional health service perspective.
Methods: We selected 10 patients with chronic dysimmune neuropathy (5 CIDP and 5 MMN) diagnosed according to
EFNS/PNS criteria. All the patients had been previously treated with IVIg (1g/Kg/month) for at least 12 months. Before swit-
ching from IVIg to SCIg it was necessary for the patient to have shown clinical improvement and to have been clinically
stabilized for at least 3 months. All the clinical assessments (MRC, ONLS, INCAT sensory sum score for CIDP) were carried
out from 7 to 15 days after the last IVIg infusion and after 6 months of SCIg treatment (final visit). Because both methods
of administration provide similar efficacies, a cost-minimization analysis was performed.
Results and Conclusions: First, costs were calculated through simulation testing different hypotheses on cost drivers.
Secondly, costs were estimated on the basis of field data collected from our patients. We considered only direct medical
costs. The results of the simulation show that the yearly direct costs to treat a patients were  € 43,456 (IVIg) and €
42,772 (SCIg). Ig acquisition costs were the main cost driver; it represented respectively 97% (SCIg) and 93% (IVIg) of the
total cost. 3%only is due to the cost of medical and nursing staff (IVIg) and 3% is due to the cost of IVIg’s side effect tre-
atment: this cost is absent for SCIg. Estimation made from the field data were found to be little different: over 6 months
the total mean cost was  € 21,088 (IVIg) and € 20,878 (SCIg). Our pilot study documents the existence of two treatments,
SCIg and IVIg, substantially equivalent as efficacy and costs for treating chronic dysimmune neuropathies. 
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